Back to Search Start Over

Cardiovascular disease risk after a SARS-CoV-2 infection: A systematic review and meta-analysis.

Authors :
Romero Starke K
Kaboth P
Rath N
Reissig D
Kaempf D
Nienhaus A
Seidler A
Source :
The Journal of infection [J Infect] 2024 Sep; Vol. 89 (3), pp. 106215. Date of Electronic Publication: 2024 Jul 04.
Publication Year :
2024

Abstract

Objectives: To our knowledge, there is no systematic review examining CVD risks after a SARS-CoV-2 infection over time, while also taking into account disease severity. All evidence on the risk for pulmonary embolism (PE), myocardial infarction (MI), ischaemic stroke (IS), haemorrhagic stroke (HS), and arterial thrombosis following infection was evaluated.<br />Methods: The protocol was registered with PROSPERO. We searched Pubmed, Embase, MedRxiv and screened the titles/abstracts and full texts. We extracted the included studies, assessed their quality, and estimated pooled risks by time after infection and according to disease severity.<br />Results: Risks were highest in the acute phase [PE: 27.1 (17.8-41.10); MI: 4.4 (1.6-12.4); stroke: 3.3 (2.1-5.2); IS: 5.6 (2.1-14.8); HS: 4.0 (0.1-326.2)] compared to the post-acute phase [PE: 2.9 (2.6-3.3); MI: 1.4 (1.1-1.9); stroke: 1.4 (1.0-2.0); IS: 1.6 (0.9-2.7)]. Highest risks were observed after infection confirmation, dropping during the first month post-infection (e.g. PE: RR(7 days) = 31; RR(1 month) = 8.1). A doubled risk was still observed until 4.5 months for PE, one month for MI and two months for IS. Risks decreased with decreasing disease severity.<br />Conclusions: Because of increased risk of CVD outcomes, management of persons who survived a severe SARS-CoV-2 infection is required, especially during the first nine months post-infection.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1532-2742
Volume :
89
Issue :
3
Database :
MEDLINE
Journal :
The Journal of infection
Publication Type :
Academic Journal
Accession number :
38971381
Full Text :
https://doi.org/10.1016/j.jinf.2024.106215